Amarantus Therapeutics makes board appointment
This article was originally published in Scrip
Executive Summary
Amarantus Therapeutics, a privately held US biotech company developing first-in-class disease-modifying treatments that address the underlying cause of apoptosis associated with a wide range of diseases, has appointed Dr Lawrence Schwartz to its scientific advisory board. He is director of the Center of Excellence in Apoptosis Research, founding director of the Pioneer Valley Life Sciences Institute and professor of biology at the University of Massachusetts Amherst.